We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genetic Screening Shows Promise During Pregnancy

By LabMedica International staff writers
Posted on 19 Jun 2012
The whole genome sequence of a human fetus has been reconstructed by analyzing blood samples from the mother and saliva samples from the father. More...


The new noninvasive technique could help screen for different types of genetic mutations in the fetus, include disorders such as cystic fibrosis, Huntington's disease, and Tay-Sachs disease, without increasing the risk of miscarriage.

Scientists at the University of Washington (Seattle, WA, USA) have opened up the possibility of assessing a fetus noninvasively for all single-gene disorders. Although fetal DNA is found in the mother's blood plasma, it can be challenging to distinguish which genetic signature belongs to the fetus and which belongs to the mother. As a result, the team used a new technique in order to identify blocks of genetic variation known as haplotypes, which could be traced back to the mother's genome.

To test the accuracy of their genetic predictions, the team collected blood from the baby's umbilical cord at birth and found that they had identified 39 of the baby's 44 new mutations during the genome reconstruction. Together with data from the father's saliva sample, they were able to determine which genomes the fetus inherited. At 18.5 weeks gestation, the scientists were able to map the whole genome of a fetus and then reconstructed it using DNA from parental samples.

Genomic DNA was extracted from whole blood with the Gentra Puregene Kit (Qiagen, Valencia, CA, USA), or from saliva, with the Oragene Dx (DNA Genotek; Kanata, ON, Canada). Purified DNA was fragmented by sonication with a Covaris S2 instrument (Woburn, MA, USA). Indexed shotgun sequencing libraries were prepared with the KAPA Library Preparation Kit (Kapa Biosystems; Woburn, MA, USA) and all libraries were sequenced on HiSeq 2000 instruments (Illumina; San Diego, CA, USA).

The techniques used by the team were able to evaluate many and more subtle variations in the fetus' genome, down to tiny, "one-letter" changes in the DNA code. Jay Shendure, MD, PhD, the lead author of the study said, "This work opens up the possibility that we will be able to scan the whole genome of the fetus for more than 3,000 single-gene disorders through a single, noninvasive test." The study was published in the June 2012 issue of the journal Science Translational Medicine.

Related Links:

University of Washington
Qiagen
DNA Genotek




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.